Amphivena Therapeutics, Inc. is an immuno-oncology company based in South San Francisco, CA that is developing best-in-class T-cell engagers as a key component of a novel biologic’s platform. The company’s lead drug candidate, AMV564, is a bivalent T cell engager that selectively depletes MDSC and leukemic blasts. AMV564 has demonstrated single-agent activity in both hematologic and solid tumor malignances. Amphivena’s mission is to eradicate cancers with breakthrough therapies that harness the patient’s own immune system to relieve immune suppression and destroy tumor cells.
We are seeking a motivated researcher to work in the development of novel therapeutics harnessing the immune system to eliminate cancer. You will play a pivotal role in the scientific direction of the research team, identifying, building and evaluating novel therapeutics and platforms. You will advance the pipeline through protein engineering and analyses of the physical properties of our platform molecules, to generate and identify superior clinical candidates for development.
Please send your CV to email@example.com